Based on clinical germline or tumor testing performed prior to enrollment, 19 patients had a germline BRCA1 (n = 6) or BRCA2 (n = 13) mutation, and 1 had a germline PALB2 mutation; 2 patients had a BRCA2 variant of uncertain significance (VUS) and 1 patient had a PALB2 VUS. Here, PALB2 is linked to neoplasm.